FDA Approved: ACIPHEX — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

FDA approved a supplemental application for ACIPHEX (rabeprazole sodium) submitted by Waylis Therapeutics LLC to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Erosive Esophagitis
• Gastric Ulcer
• Gastritis Erosive
• Gastroesophageal Reflux Disease
• Nsaid-associated Gastric Ulcer

Drugs mentioned

• ACIPHEX (rabeprazole sodium)

Snippet

SUPPL AP for ACIPHEX (RABEPRAZOLE SODIUM)